NICE recommends mifamurtide as a possible treatment for some children, adolescents and young adults with osteosarcoma.
Who can have mifamurtide?
Children, adolescents and young adults should be able to have mifamurtide if:
- their tumour is high-grade and non-metastatic and
- they have had an operation to remove the tumour and
- they are also having chemotherapy with multiple drugs.
Why has NICE said this?
NICE looks at how well treatments work, and also at how well they work in relation to how much they cost the NHS. NICE recommended mifamurtide because more people are cured if they have mifamurtide as well as chemotherapy, and the cost was justified by the benefits it provided.
The recommendations in this guidance represent the view of NICE, arrived at after careful consideration of the evidence available. When exercising their judgement, health professionals are expected to take this guidance fully into account, alongside the individual needs, preferences and values of their patients. The application of the recommendations in this guidance is at the discretion of health professionals and their individual patients and do not override the responsibility of healthcare professionals to make decisions appropriate to the circumstances of the individual patient, in consultation with the patient and/or their carer or guardian.
Commissioners and/or providers have a responsibility to provide the funding required to enable the guidance to be applied when individual health professionals and their patients wish to use it, in accordance with the NHS Constitution. They should do so in light of their duties to have due regard to the need to eliminate unlawful discrimination, to advance equality of opportunity and to reduce health inequalities.
Commissioners and providers have a responsibility to promote an environmentally sustainable health and care system and should assess and reduce the environmental impact of implementing NICE recommendations wherever possible.